Study on HCMV Infection in Pregnant Women

Immunological and Virological Prognostic Markers of Human Cytomegalovirus (HCMV) Congenital Infection in Pregnant Women With Primary HCMV Infection.

Recruiting Observational Study
Human Cytomegalovirus (HCMV)
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Study type
Observational
Participants needed
90 (estimated)
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia · Other
Who this trial is looking for

This trial is looking for pregnant women who recently had a primary infection of the Human Cytomegalovirus (HCMV). Participants will help researchers learn more about how this infection affects them and their babies.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am a pregnant woman over 18 years old.
  • I had a primary HCMV infection within the first 26 weeks of my pregnancy.
  • My primary HCMV infection started within the last 3 months.
  • I have a history of HCMV infection before pregnancy.
  • I have a newborn who is congenitally infected with HCMV.

You may not be able to join if

  • I am infected with HBV, HCV, or HIV.
  • I have known immunodeficiency or an autoimmune disease.
  • I cannot follow the requirements of the study.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Human cytomegalovirus (HCMV) establishes a lifelong relationship with its host: primary infection is followed by a latency phase with intermittent reactivation episodes, despite a robust, long-lasting immune response. Primary and non-primary infection (the latter indicating both reactivation and re-infection) is usually asymptomatic in immunocompetent individuals. Apart from immunocompromised sub…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Pregnant women \>18 years. * HCMV primary infection occurring within 26 weeks of gestation. * HCMV primary infection onset within 3 months before enrollment. * HCMV pre-conception (non-primary) infection and congenitally infected newborn Exclusion Criteria: * HBV, HCV, HIV i…
Contacts

No contact information available.